Humana Inc. reported adjusted earnings per share of $8.04 for Q1 2022, exceeding the Zacks Consensus Estimate of $6.83 and marking the fifth consecutive year of surpassing earnings expectations. The company also posted consolidated revenues of $23.97 billion, fueled by a $930 million net income and a year-over-year EPS increase from $7.67. As a response to its strong performance, Humana raised its full-year earnings guidance to $24.50 per share and projected Medicare Advantage membership growth of 150,000 to 200,000 members. Despite the challenges posed by ongoing COVID-19 related costs, Humana's stock maintains a Zacks Rank #2 (Buy), suggesting continued investor confidence.
“Humana · reported · first-quarter 2022 adjusted earnings per share · $8.04”
“Humana · improved · bottom line · from the year-ago figure of $7.67 per share”
“Humana · has beaten · the Zacks quarterly earnings estimates · for five years running”
“Humana · reported · first-quarter 2022 adjusted earnings per share · $8.04”
“The company · saw · a year-over-year increase in revenue · $20.6 billion reported for the same quarter of 2021”
“Humana Inc. · is committed to · helping our millions of medical and specialty members achieve their best health”
“Susan M. Diamond · is · Chief Financial Officer · Humana Inc.”
“Humana Inc. · offers · a range of clinical capabilities, resources and tools”
“Humana Inc. · supports · physicians and other health care professionals · delivering the right care in the right place for their patients, our members”
“Humana Inc. · had · adjusted earnings per share · $8.04”
“Humana Inc. · surpassed · Zacks Consensus Estimate · $6.83”
“Humana Inc. · improved from · year-ago figure · $7.67 per share”